Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China
April 24, 2017 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based...
Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017
April 18, 2017 12:00 ET
|
Paratek Pharmaceuticals
- Oral presentation: Phase 3 omadacycline IV-to-oral ABSSSI results (OASIS) - Poster presentation: Health Economics - omadacycline vs. commonly-used antibiotic therapies BOSTON, April ...
Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia
April 03, 2017 16:01 ET
|
Paratek Pharmaceuticals
Omadacycline met all FDA primary and secondary endpoints and EMA co-primary endpointsOmadacycline was generally safe and well toleratedU.S. New Drug Application planned as early as Q1 2018Company to...
Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
March 27, 2017 07:30 ET
|
Paratek Pharmaceuticals
DUBLIN, Ireland and BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- Allergan plc, (NYSE:AGN), a leading global pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical...
Paratek Pharmaceuticals Opens New Office in King of Prussia
March 24, 2017 08:00 ET
|
Paratek Pharmaceuticals
KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update
March 02, 2017 07:30 ET
|
Paratek Pharmaceuticals
Advanced timing for top-line data readout of Phase 3 study of omadacycline in community-acquired bacterial pneumonia (CABP)Conference call scheduled for 8:30 a.m. EST on March 2, 2017 BOSTON, March ...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
February 22, 2017 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals, Inc. to Present at LEERINK Partners 6th Annual Global Healthcare Conference
February 08, 2017 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Operating Officer, Evan Loh, MD, will participate in the LEERINK...
Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study
January 18, 2017 07:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 18, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon...
Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer
January 04, 2017 08:00 ET
|
Paratek Pharmaceuticals
- Evan Tzanis promoted to Senior Vice President, Clinical Development and Clinical Operations - Jeanne Jew promoted to Senior Vice President, Business Development BOSTON,...